Use of proton pump inhibitors in patients with COVID-19 infection: Are we doing more harm than good?
DOI:
https://doi.org/10.47672/ejhs.605Keywords:
Pandemic, COVID-19, SARS-CoV-2, proton pump inhibitorsAbstract
Purpose: The purpose of this paper was to highlight the use of proton pump inhibitors (PPIs) in the supportive treatment of COVID-19 infection and the potential effects associated with their use.
Methodology: This was a theoretical paper.
Findings: COVID-19 pandemic has had a profound negative impact worldwide on the economic and healthcare machinery. PPIs are important drugs used as supportive therapy for various medical conditions like heart-burn and acid peptic disease. There is an on-going deliberation regarding the probable useful versus deleterious effects of PPI use in patients with COVID-19 infection. Some authorities believe in their usefulness as anti-oxidant and anti-inflammatory agents, while others prove with evidence the potential harm caused by their use in terms of increased vulnerability to infections.
Recommendation: Given their possible side-effects, prudent usage of PPI therapy is warranted in patients with active COVID-19 infection.
Keywords: Pandemic, COVID-19, SARS-CoV-2, proton pump inhibitors
Downloads
References
Zhu, F. C., Li, Y. H., Guan, X. H., Hou, L. H., Wang, W. J., Li, J. X., Wu, S. P., Wang, B. S., Wang, Z., Wang, L., Jia, S. Y., Jiang, H. D., Wang, L., Jiang, T., Hu, Y., Gou, J. B., Xu, S. B., Xu, J. J., Wang, X. W., Wang, W., "¦ Chen, W. (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London, England), 395(10240), 1845-1854.
Metz D. C. (2000). Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion, 62(2-3), 73-81.
Kazberuk, M., Brzósko, S., Hryszko, T., & Naumnik, B. (2016). Overuse of proton pump inhibitors and its consequences. Postepy higieny i medycyny doswiadczalnej (Online), 70(0), 1112-1116.
Vaezi, M. F., Yang, Y. X., & Howden, C. W. (2017). Complications of Proton Pump Inhibitor Therapy. Gastroenterology, 153(1), 35-48.
Xie, Y., Bowe, B., Yan, Y., Xian, H., Li, T., & Al-Aly, Z. (2019). Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ (Clinical research ed.), 365, l1580.
Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., & Shan, H. (2020). Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology, 158(6), 1831-1833.e3.
Zhou, J., Li, C., Zhao, G., Chu, H., Wang, D., Yan, H. H., Poon, V. K., Wen, L., Wong, B. H., Zhao, X., Chiu, M. C., Yang, D., Wang, Y., Au-Yeung, R., Chan, I. H., Sun, S., Chan, J. F., To, K. K., Memish, Z. A., Corman, V. M., "¦ Yuen, K. Y. (2017). Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Science advances, 3(11), eaao4966.
Trottein, F., & Sokol, H. (2020). Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. Cell reports, 32(3), 107915.
Goncalves Mendes Neto, A., Lo, K. B., Wattoo, A., Salacup, G., Pelayo, J., DeJoy, R., 3rd, Bhargav, R., Gul, F., Peterson, E., Albano, J., Patarroyo-Aponte, G., Rangaswami, J., & Azmaiparashvili, Z. (2020). Bacterial infections and patterns of antibiotic use in patients with COVID-19. Journal of medical virology, 10.1002/jmv.26441. Advance online publication.
TaÅŸtemur, Åž., & Ataseven, H. (2020). Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?. Medical hypotheses, 143, 110018.
Lee, S. W., Ha, E. K., Yeniova, A. Ö., Moon, S. Y., Kim, S. Y., Koh, H. Y., Yang, J. M., Jeong, S. J., Moon, S. J., Cho, J. Y., Yoo, I. K., & Yon, D. K. (2020). Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut, gutjnl-2020-322248. Advance online publication.
Luxenburger, H., Sturm, L., Biever, P., Rieg, S., Duerschmied, D., Schultheiss, M., Neumann-Haefelin, C., Thimme, R., & Bettinger, D. (2020). Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?. Journal of internal medicine, 10.1111/joim.13121. Advance online publication.
Cui, S., Chen, S., Li, X., Liu, S., & Wang, F. (2020). Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of thrombosis and haemostasis : JTH, 18(6), 1421-1424.
Patel, P., & Sengupta, N. (2020). PPIs and Beyond: A Framework for Managing Anticoagulation-Related Gastrointestinal Bleeding in the Era of COVID-19. Digestive diseases and sciences, 65(8), 2181-2186.
Freedberg, D. E., Conigliaro, J., Wang, T. C., Tracey, K. J., Callahan, M. V., Abrams, J. A., & Famotidine Research Group (2020). Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology, 159(3), 1129-1131.e3.
Cheung, K. S., Hung, I. F., & Leung, W. K. (2020). Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study. Gastroenterology, S0016-5085(20)34940-4. Advance online publication.
Price E. (2020). Could the severity of COVID-19 be increased by low gastric acidity?. Critical care (London, England), 24(1), 456.
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
